Expression of lncRNA HULC in papillary thyroid carcinoma tissues

doi:10.3969/j.issn.1673-8640.2022.07.001

Abstract

Abstract:

Objective To investigate the expression of long non-coding RNA（lncRNA）highly up-regulated in liver cancer（HULC） in papillary thyroid carcinoma（PTC） tissues,and to study the effect of interfering with this gene on cell proliferation activity and invasiveness. Methods A total of 105 patients with PTC who underwent surgical treatment were enrolled. The PTC tissues removed during the operation and the adjacent tissues more than 2 cm from the tumor edge were collected. The relative expression level of HULC was determined by real-time fluorescence quantitative polymerase chain reaction（RT-qPCR）. The TPC-1 cells were transfected with different sequences. According to the different transfection sequences of TPC-1 cells,they were classified into si-HULC group（transfected with small molecule interference sequence of HULC）,si-Con group（transfected with negative control sequence） and blank group（not transfected）. The expression of HULC,cell proliferation activity and invasiveness in each group were determined. Results The relative expression level of HULC in PTC tissues was higher than that in adjacent tissues（P<0.001）. The differences of the expression levels of HULC in PTC tissues with different tumor diameters,TNM stages and lymph node metastasis had statistical significance（P<0.05）. There was no statistical significance for the expression levels of HULC in PTC tissues with different ages,sex,the numbers of lesions and the types of local invasion（P>0.05）. The relative expression level of HULC,cell proliferation activity and the number of invasive cells in si-HULC group were lower than those in si-Con group and blank group（P<0.05）,and there was no statistical significance between si-Con group and blank group（P>0.05）. Conclusions The expression of HULC in PTC tissues is increased,and it is related to tumor size,TNM stage and lymph node metastasis. Interfering with HULC expression in TPC-1 cells can inhibit cell proliferation activity and invasiveness.

Key words: Highly up-regulated in liver cancer, Long non-coding RNA, Proliferation activity, Invasiveness, Papillary thyroid carcinoma

CLC Number:

R446.7

JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues[J]. Laboratory Medicine, 2022, 37(7): 605-609.

Figures/Tables 3

References 15

[1]	韩婧, 康骅. 甲状腺癌的发病现状及影响因素[J]. 实用预防医学, 2018, 25(7):894-897.
[2]	彭旭红, 李佳, 王玉, 等. AKR1B10在甲状腺乳头状癌组织中的表达及其临床意义[J]. 中国癌症防治杂志, 2019, 11(5):416-420.
[3]	AGRAWAL V R, HRENO J, PATIL T, et al. New therapies for anaplastic thyroid cancer[J]. Drugs Today(Barc), 2018, 54(11):695-704.
[4]	ZHAO H, HUANG T, LI H. Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer[J]. Surgery, 2019, 166(1):55-60. DOI URL
[5]	SANCHEZ CALLE A, KAWAMURA Y, YAMAMOTO Y, et al. Emerging roles of long non-coding RNA in cancer[J]. Cancer Sci, 2018, 109(7):2093-2100. DOI URL
[6]	ZHANG H, LIAO Z, LIU F, et al. Long noncoding RNA HULC promotes hepatocellular carcinoma progression[J]. Aging(Albany NY), 2019, 11(20):9111-9127.
[7]	徐飞, 刘九洋, 黄超群, 等. 长链非编码RNA HULC在结直肠癌中的表达及预后价值[J]. 武汉大学学报(医学版), 2018, 39(2):244-247.
[8]	杨美丰, 任宏波. lncRNA HULC在弥漫性大B细胞淋巴瘤患者中表达及其临床意义[J]. 中华实用诊断与治疗杂志, 2019, 33(2):128-131.
[9]	ZHAN S, LUO D, GE W, et al. Clinicopathological predictors of occult lateral neck lymph node metastasis in papillary thyroid cancer:a meta-analysis[J]. Head Neck, 2019, 41(7):2441-2449. DOI URL
[10]	DING Y, SUN C, LI J, et al. The significance of long non-coding RNA HULC in predicting prognosis and metastasis of cancers:a meta-analysis[J]. Pathol Oncol Res, 2019, 25(1):311-318. DOI URL
[11]	叶华, 何波, 陈捷, 等. 长链非编码RNA HULC在胆管癌中促进细胞迁移和侵袭的机制[J]. 中华实验外科杂志, 2019, 36(8):1401-1405.
[12]	WANG L Y, LI R L, GUO M, et al. Long noncoding RNA HULC promoter polymorphism rs1041279 is associated with an increased risk of cervical squamous cell carcinoma[J]. Reprod Sci, 2020, 27(1):93-99. DOI PMID
[13]	ZHANG Y, SONG X, WANG X, et al. Silencing of LncRNA HULC enhances chemotherapy induced apoptosis in human gastric cancer[J]. J Med Biochem, 2016, 35(2):137-143. DOI URL
[14]	LIU L, ZHOU X Y, ZHANG J Q, et al. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1(SPHK1) and its downstream PI3K/Akt pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(24):8722-8730.
[15]	苏文, 王宇帆, 王锋, 等. 肝细胞癌上调的长链非编码RNA对口腔鳞状细胞癌细胞生物学行为的影响[J]. 中华口腔医学杂志, 2018, 53(11):760-765.

临床病理特征	例数	HULC	临床病理特征	例数	HULC
年龄			局部侵犯
>47岁	45	2.53±0.21	腺内型	41	2.47±0.19
≤47岁	60	2.49±0.18	腺外型	64	2.53±0.20
t值		0.896	t值		1.381
P值		0.373	P值		0.170
性别			TNM分期
男性	31	2.46±0.18	Ⅰ~Ⅱ期	68	2.46±0.17
女性	74	2.53±0.20	Ⅲ~Ⅳ期	37	2.58±0.21
t值		1.641	t值		3.060
P值		0.104	P值		0.003
肿瘤直径			淋巴结转移
≤2 cm	66	2.47±0.17	有	39	2.60±0.21
>2 cm	39	2.57±0.21	无	66	2.45±0.16
t值		2.682	t值		4.098
P值		0.009	P值		<0.001
病灶数量
单个	71	2.48±0.19
多个	34	2.55±0.20
t值		1.713
P值		0.090

临床病理特征	例数	HULC	临床病理特征	例数	HULC
年龄			局部侵犯
>47岁	45	2.53±0.21	腺内型	41	2.47±0.19
≤47岁	60	2.49±0.18	腺外型	64	2.53±0.20
t值		0.896	t值		1.381
P值		0.373	P值		0.170
性别			TNM分期
男性	31	2.46±0.18	Ⅰ~Ⅱ期	68	2.46±0.17
女性	74	2.53±0.20	Ⅲ~Ⅳ期	37	2.58±0.21
t值		1.641	t值		3.060
P值		0.104	P值		0.003
肿瘤直径			淋巴结转移
≤2 cm	66	2.47±0.17	有	39	2.60±0.21
>2 cm	39	2.57±0.21	无	66	2.45±0.16
t值		2.682	t值		4.098
P值		0.009	P值		<0.001
病灶数量
单个	71	2.48±0.19
多个	34	2.55±0.20
t值		1.713
P值		0.090

组别	12 h	24 h	48 h	72 h	96 h
si-HULC组	0.33±0.03	0.81±0.08^*#	1.83±0.05^*#	2.53±0.08^*#	3.64±0.04^*#
si-Con组	0.37±0.04	1.34±0.10	2.45±0.12	3.57±0.09	4.75±0.07
空白组	0.34±0.09	1.28±0.12	2.50±0.18	3.61±0.06	4.69±0.05
F值	0.760	47.129	50.149	359.091	795.531
P值	0.485	<0.001	<0.001	<0.001	<0.001

组别	12 h	24 h	48 h	72 h	96 h
si-HULC组	0.33±0.03	0.81±0.08^*#	1.83±0.05^*#	2.53±0.08^*#	3.64±0.04^*#
si-Con组	0.37±0.04	1.34±0.10	2.45±0.12	3.57±0.09	4.75±0.07
空白组	0.34±0.09	1.28±0.12	2.50±0.18	3.61±0.06	4.69±0.05
F值	0.760	47.129	50.149	359.091	795.531
P值	0.485	<0.001	<0.001	<0.001	<0.001